$VICR

Davies Philip D sold $650K of VICR

Davies Philip D (Corp. VP-Global Sales & Mktg.) sold 3,072 shares of VICOR CORP (VICR) at an average of $211.69 ($200.06–$216.04, $0.65M total) across 9 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Philip D
Published Aug 5, 2026, 3:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 3:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
medium confidence
Mentioned
$VICR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

Traders may monitor for patterns in insider activity, but this specific disclosure does not introduce new guidance, contracts, litigation, or operational changes.

02

Market read

A disclosed insider sale of roughly $650K in VICR, dated 2026-08-03 and filed 2026-08-05, with no accompanying company-specific catalyst.

03

What to watch

The net effect depends on whether there are offsetting insider buys or other contemporaneous disclosures, which are not provided in this article.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction for ViCOR Corp, reporting an officer’s open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$VICRNeutralMedium confidence
Context

ViCOR Corp insider Davies Philip D sold about $650.3K of VICR shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Near-term impact is likely limited; any reaction would be sentiment-driven and typically fades as 10b5-1 sales are expected.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific news beyond the sale details.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax planning and may not reflect bearish expectations, especially when executed under a 10b5-1 plan.

Key entities

  • VICOR CORP

    Company whose insider transaction is disclosed on SEC Form 4.

  • Davies Philip D

    Corp. VP-Global Sales & Mktg., officer/director who sold shares.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: